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Somatostatin receptor subtype mRNA expression in
human colorectal cancer and normal colonic mucosae
SAM Laws1, AC Gough', AA Evans1, MA Bains2 and JN Primrose1
University Departments of 'Surgery and 2Histopathology, Southampton General Hospital, Hampshire S016 6YD, UK
Summary Somatostatin analogues may be useful novel agents in the systemic treatment of advanced colorectal cancer, as somatostatin
inhibits proliferation in a wide variety of cell types. Here, we report the expression profiles of somatostatin receptor mRNAs in 32 pairs of
malignant and normal colonic epithelia. Receptor subtype 2 (hSSTR2) mRNA was detected throughout nearly 90% of both malignant and
normal tissue by reverse transcription-polymerase chain reaction (RT-PCR) and in situ hybridization. Subtype 5 (hSSTR5) mRNA was
detected in 46% and 45% of tumour and mucosal samples respectively, but in 75% (9/12) of early-stage tumours (tubulovillous adenomas,
Dukes' A and B) compared with 31% (5/16) of late-stage tumours (Dukes' C and 'D' tumours), 0.05>P>0.025 (X2with Yates' correction). There
was also reduced expression of hSSTR5 in samples of metastatic tumour (11%, 1/9) compared with all tumour samples (56%, 18/32)
0.025>P>0.01 (X2 with Yates' correction). Other hSSTRs (1, 3 and 4) were expressed infrequently. Thus, hSSTR2 expression is retained after
malignant transformation in colonic epithelium and, although it may potentially be a target for antiproliferative therapy, its ubiquitous
expression militates against this. hSSTR5 warrants investigation as a tumour suppressor.
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Colorectal cancer is one of the major causes of cancer-related
mortality in the western world, accounting for 12% of all cancer
deaths annually in England and Wales and the USA (Cancer
Research Council factsheet 1, 1990; NIH Consensus Conference,
1990). Regrettably, there has been no major improvement in
survival in the last 40 years, despite advances in surgery and
systemic therapy (Cancer Research Council factsheet 18, 1993).
As many patients present with disease at an advanced stage,
there is an urgent need for the development of systemic therapies,
which improve both quality of life and survival in patients with
late-stage tumours. One such treatment strategy may involve the
use of somatostatin analogues. Somatostatin was initially isolated
as a growth hormone release-inhibiting factor and has subse-
quently been found to be a pan-inhibitory peptide, which inhibits
proliferation in a wide variety ofcell types, even following malig-
nant transformation (Patel et al, 1981). There is evidence that this
antiproliferative activity may be caused by a number of mecha-
nisms, including inhibition of release of stimulatory systemic
hormones and growth factors (Patel et al, 1981), inhibition of
angiogenesis (Woltering et al, 1990), immunomodulation (Partsch
et al, 1992) and direct action through high-affinity, cell-surface
receptors (Pagliacci et al, 1991; Buscail et al, 1994). Five high-
affinity, cell-surface somatostatin receptors of the seven-trans-
membrane, G-protein-coupled type have been identified and their
genes sequenced (Yamada et al, 1992a, b, 1993; Rohrer et al,
1993; O'Carroll et al, 1993). They couple to G-protein a subunits,
which variously inhibit the activity of adenyl cyclase (Gal/2),
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prevent intracellular calcium rises (GaO) (Bell and Reisine, 1993)
and may also stimulate the activity of protein phosphatases
(Buscail et al, 1995), leading to the abrogation of intracellular
stimulatory signals and transmodulation of tyrosine kinase-type
receptors, for example, the epidermal growth factor receptor
(Pinski et al, 1994). The receptor subtypes also have different
biochemical characteristics, including variable binding affinities
for somatostatin 14 (SS14), somatostatin 28 (SS28), which is
involved in the regulation of colonic motility (Bitar and Kothary,
1994), and synthetic analogues (Raynoret al, 1993; Lamberts et al,
1996). Subtype 5 is the only receptor that has a higher relative
binding affinity for SS28 than SS14 (O'Carroll et al, 1993). Thus,
the effect of somatostatin or its analogues on a tissue will depend
on both the receptor subtype expressed and on signalling pathway
recruitment.
Previous studies on somatostatin receptor expression have
detected subtypes 1,2 and 5 in gastrointestinal tissue and cell lines
(Yamada et al, 1992a, b; Eden and Taylor, 1993; O'Carroll et al,
1993) and hSSTR3 in the pancreas (Yamada et al, 1993). How-
ever, studies of colonic tissues have yielded different results with
diverse methodologies (Miller et al, 1992; Reubi et al, 1994), and
none of the methods used allow discrimination between the five
receptor subtypes. In this study, we have determined hSSTR
subtype gene expression in a series of matched normal and malig-
nant colonic epithelia and metastases using the molecular biolog-
ical techniques ofreverse transcription-polymerase chain reaction
(RT-PCR) and in situ hybridization (ISH), both of which enable
the identification ofreceptor subtypes.
MATERIALS AND METHODS
Thirty-two colorectal cancer specimens, 31 mucosal specimens
and 9 metastatic specimens (Table 1) were obtained fresh, snap
frozen in liquid nitrogen and stored at -80°C. Total RNA was
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Table 1 Patient characteristics - primary tumour and metastases
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M, male; F, female. Grade is degree of differentiation (dyspl, dysplasia).
Stage is modified Dukes' staging [Tv, tubulovillous adenoma; met, metastasis
(site of primary given)]. hSSTR 1-5, somatostatin receptor subtypes. T,
primary or metastatic tumour; M, mucosa.
extracted using the RNeasy kit (Qiagen, Dorking, Surrey, UK) and
treated with 0.75 U RNAase-free DNAaseI (Pharmacia, St Albans,
Herts, UK) according to the manufacturer's instructions. DNAase
treatment is essential, as somatostatin receptor genes have no
introns. The presence ofDNA contamination was tested by DNA-
specific PCR amplification ofthe glyceraldehyde phosphate dehy-
drogenase gene (GAPDH).
Reverse transcription was performed by 400 U MMLV-RT
(Gibco BRL, Paisley, UK) in 1 x manufacturer's buffer containing
0.5 mM dNTPs, 10 mM DTT, 15 U placental RNAase inhibitor and
2 gg of pdT(12-18) primer (Pharmacia). RNA and RT integrity
was verified by amplification of the ubiquitously expressed P-
actin gene. Thermal cycling was performed by the use of somato-
statin receptor subtype-specific primers (Table 2) at 1 gM final
concentration using 50 ,UM each dNTP, 1 U Taq polymerase
Table 2 Primer sequences used for subtype-specific PCR
Target and direction Primer sequences (5'-3')
hSSTR1 Forward TATCTGCCTGTGCTACGTG
hSSTR1 Reverse GATGACCGACAGCTGACTCA
hSSTR2 Forward ATCTGGGGCTTGGTACACAG
hSSTR2 Reverse CTTCTTCCTCTTAGAGGAAGCCC
hSSTR3 Forward TCAGTCACCAACGTCTACATCC
hSSTR3 Reverse ACGCTCATGACAGTCAGGC
hSSTR4 Forward CGCTCGGAGAAGAAAATCAC
hSSTR4 Reverse CCCACCTTTGCTCTTGAGAG
hSSTR5 Forward CGTCTTCATCATCTACACGG
hSSTR5 Reverse GGCCAGGTTGACGATGTTGA
fI-actin Forward TGACGGGGTCACCCACACTGTGCCCATCTA
f-actin Reverse CTAGAAGCATTTGCGGTGGACGATGGAGGG
(Amersham, Little Chalfont, Bucks, UK) in manufacturer's buffer
containing 2 mm magnesium chloride and dimethyl sulphoxide
(DMSO; Sigma, Poole, Dorset, UK) at 2% (v/v) for hSSTR 1 and
5 and 5% for hSSTR4. Cycling was carried out on a Techne PHC3
thermal cycler with an initial denaturing step of 3 min at 94°C,
followed by 35 cycles of 94°C denaturation for 30 s, annealing at
55°C for 30s and 72°C polymerization for 30s. This was followed
by a final step of 72°C for 2 min to ensure completion of all initi-
ated polymerization events. The annealing temperature used,
550C, is close to the Tm for all primers at the specific salt and
DMSO concentrations used, thus ensuring subtype-specific ampli-
fication. Products were resolved on 8% non-denaturing polyacry-
lamide gel, stained with ethidium bromide and visualized by UV
transillumination. Each sample of tumour/mucosa was analysed
on three separate occasions. Confirmation of subtype-specific
PCR was by restriction mapping, correct product size on gel elec-
trophoresis and sequencing (data not shown). Genomic DNA was
used as positive control for PCR amplifications.
Tissue histology was performed by a single pathologist using
standard protocols. Dukes' grade 'D' has been included to repre-
sent all samples of primary tumour in which distant metastases
were present at the time ofthe initial resection.
In situ hybridization (ISH) was performed on ten representative
matched tumour mucosa pairs and two metastases with a 148-bp
digoxigenin-labelled riboprobe for hSSTR2, 222 bp for hSSTR5
and oligonucleotides specific for hSSTRI. Cryostat sections (7
gm) of the snap-frozen tumour were taken, allowed to air dry and
fixed for 5 min in 4% paraformaldehyde at 4°C. They were then
washed twice for 10 min in Hanks' balanced salt solution (Sigma).
Sections were prehybridized in 50% deionized formamide, 0.5 M
Tris, 1% sodium pyrophosphate, 2% polyvinyl pyrrolidone, 2%
Ficoll, 50 mm EDTA, 0.6 M sodium chloride, 500 jg ml-' tRNA
and 10% dextran sulphate (Sigma) for 1 h at 42°C. Hybridization
was carried out overnight at 42°C with 500 jig ml-' riboprobe in
prehybridization solution. Washing was performed with one
manual wash of 2 x standard saline citrate (SSC) and two 10-min
washes in 1 x SSC, including 30% formamide at 420C. Sections
were then blocked in 3% bovine serum albumin (BSA) in 50 mM
Tris, 150 mm sodium chloride and 2 mm magnesium chloride and
0.1% (V/V) Triton xlO0 (Sigma) for 30 min at room temperature.
Alkaline phosphatase-conjugated antidigoxigenin antibody
(Boehringer Mannheim, Lewes, Sussex, UK) was then added for
45 min. Sections were washed twice for 5 min in a 1:30 dilution of
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Table 3 hSSTR subtype expression as determined by RT-PCR in different tissues
Tissue Number of samples hSSTR 1 hSSTR 2 hSSTR 3 hSSTR 4 hSSTR 5
Mucosa 31 8 (26%) 27 (87%) 4 (13%) 3 (10%) 14 (45%)
Tumour 32 11 27 9 4 18
Metastases 9 0 9 0 0 1
Tumour and metastases 41 11 (27%) 35 (87%) 9 (22%) 4 (10%) 19 (46%)
Table 4 hSSTR expression in neoplastic samples by tumour stage (A,B,C and 'D' are modified Dukes' stage)
Stage Number of samples hSSTR 1 hSSTR 2 hSSTR 3 hSSTR 4 hSSTR 5
(%) (%) (%) (%) (%)
Tubulovillous 4 2 (50) 2 (50) 2 (50) 0 (0) 4 (100)
A 2 1 (50) 1 (50) 0 (0) 0 (0) 1 (50)
B 10 4(40) 10(100) 4(40) 1 (10) 8(80)
C 14 4 (28) 12 (86) 3 (21) 3 (21) 4 (29)
'D' 2 0 (0) 2 (100) 0 (0) 0 (0) 1 (50)
Metastases 9 0 (0) 9 (100) 0 (0) 0 (0) 1 (11)
All 41 11 (27) 36 (88) 9 (22) 4 (10) 19 (46)
blocking solution, equilibrated in substrate buffer at 100 mM Tris,
pH 9.5, 200 mm sodium chloride and 50 mm magnesium chloride.
After the addition of substrate, 0.8% nitrophenol blue, 0.8% 5-
bromo 4-chloro 3-indolyl phosphate and levamisole (100 mM)
(Boehringer Mannheim), the sections were incubated in the dark
for 1-3 h at room temperature, baked at 80°C in aqueous mounting
medium for 20 min and mounted in DPX mounting medium
(Raymond Lamb, London, UK). All prehybridization solutions
were guaranteed RNAase free.
Statistical analysis was performed using X2 with Yates' correction
on Clinical Statistics System Version 1.01 OClinical Statistics 1993.
RESULTS
Confirmation ofRNA integrity was carried out by RT-PCR ampli-
fication of the constitutively expressed 3-actin gene. As the
somatostatin receptors are primarily encoded by single exons, all
RNA samples were treated with DNAase and subsequently
analysed for DNA contamination using DNA-specific primers.
There was no amplification of a GAPDH gene fragment after
DNAase treatment (results not shown).
The results of RT-PCR determination of hSSTR subtype
expression are shown in Table 3 and stage-specific expression in
malignant tissue in Table 4. The majority (87%) of normal
mucosae and malignant tissues expressed hSSTR2. hSSTR5 was
expressed in 45% of mucosal and 46% of malignant samples.
However, when analysed by stage, expression was significantly
different between early-stage tumours (Dukes' A and B) and late-
stage tumours (Dukes' C and 'D' tumours), 75% (9/12) and 31%
(5/16) respectively, 0.05>P>0.025 (X2 with Yates' correction).
Only 11% (1/9) of metastases expressed hSSTR5 compared with
56% (18/32) ofall primary tumours, 0.025>P>0.01 (%2 with Yates'
correction). The expression ofhSSTR 1, 3 and 4 was rare and in no
discernible pattern. There was no correlation of expression with
tumour site or grade for any of the five receptors, and mucosal
expression matched tumour expression in the vast majority of
tissue pairs.
The ISH technique was verified by using a mitochondrial RNA
oligonucleotide cocktail probe (C21, a gift from Dr JH Pringle,
Department of Pathology, University of Leicester, UK) as a posi-
tive control for tissue integrity (results not shown). Sense probes
were used as negative controls for non-specific probe binding.
Results of ISH using oligonucleotides for hSSTR1 were identical
to PCR results, with positive staining only being observed in two
samples (results not shown). Probe distribution in tumour samples
was ubiquitous throughout viable malignant tissue. hSSTR2
mRNA was present throughout all malignant epithelia and was
especially dense in some of the earlier stage tumours. Generally,
tumour staining was more dense than mucosal staining, which
appeared strongest in basal epithelial cells and some stromal cells
(Figure IA and C). Metastases also expressed hSSTR2 mRNA in
all viable malignant cells. There was no loss of hSSTR2 expres-
sion in any population ofmalignant cells. In contrast, hSSTR5 was
expressed in only half of the tumours examined, and unstained
areas were clearly visible within the sections (Figure IE).
DISCUSSION
The failure of conventional systemic therapies to improve the
outlook for patients with advanced colorectal cancer significantly
(Cancer Research Campaign factsheet 18, 1993) makes the need
for alternative approaches urgent. As most patients die of surgi-
cally untreatable disease, treatments that improve length and
quality of life but do not result in systemic toxicity would be valu-
able, even if they prove to be palliative. One such treatment
strategy may involve the use of somatostatin analogues, as they
have inherent antiproliferative properties and exhibit minimal toxi-
city (Patel et al, 1981). As a preliminary to the rational evaluation
of these agents in the treatment of patients with advanced
colorectal cancer, we have mapped the distribution ofsomatostatin
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Figure 1 Hybridized cryostat sections of normal colonic mucosa (A and B), primary colonic tumour (C and D) and metastases (E and F). (A and C) have been
hybridized with an hSSTR2 antisense riboprobe, (B and D) with the hSSTR2 sense probe and (E and F) with antisense and sense probes for hSSTR5
respectively (see Materials and methods). All cells appeared viable on haematoxylin and eosin sections (not shown). Bar=30lam.
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receptor subtypes in samples of normal and malignant colorectal
epithelium.
These studies on somatostatin receptor distribution used molec-
ular methodologies. Hence, the results should be interpreted with
some caution as steady-state mRNA levels do not necessarily indi-
cate the presence of a functionally coupled receptor protein.
However, none of the other methodologies currently in use
can distinguish between the five receptor subtypes. We used
RT-PCR, a technique that is proven to be semi-quantitative in our
laboratory (AC Gough and HS Chave, University Surgical Unit,
Southampton, unpublished observation) rather than Northern
analysis, because of its unparalleled sensitivity, which is impor-
tant, particularly when only small pieces of tissue are available.
By contrast, in situ hybridization is less sensitive but reveals
cellular localization, which is necessary to complement the results
of the RT-PCR.
Expression ofthe hSSTR2 gene appeared widely distributed and
relatively homogeneous throughout cancer cells, normal mucosae
and stromae in the vast majority of samples analysed. hSSTR5 is
expressed in approximately half of normal mucosal samples and
tumours. However, in situ studies show that, in contrast with
hSSTR2, the expression is confined to the mucosal and cancer
cells and is often patchy. It is interesting to note that metastases
express hSSTR5 significantly less frequently than primary
tumours or mucosal samples. Observation also suggests that early
tumours and adenomas are more likely to express hSSTR5 than
advanced tumours. However, many more tumours would have to
be studied in order to validate fully the relationship of expression
to tumour stage and prognosis. It is possible that hSSTR5 is acting
as a tumour suppressor, and we are currently investigating this
possibility further.
hSSTR5 is the only receptor with a higher affinity for somato-
statin 28 (O'Carroll et al, 1993), a peptide found in colonic epithe-
lium and involved in the regulation of colonic motility (Bitar and
Kotharny, 1994). It is unclear why only a proportion ofsamples of
normal mucosa express hSSTR5, especially since its expression is
common in early neoplasms. This finding also warrants further
investigation.
Using RT-PCR, we were able to demonstrate the expression of
hSSTR1, 3 and 4 in colon cancer and colonic mucosa relatively
infrequently. It is interesting to note that hSSTR1 expression in
colonic tissue is not confined to neuroendocrine cells. In situ
hybridization using probes for hSSTR1 showed that the expres-
sion, where present, was in both mucosa and cancer tissue. In the
past,the hSSTR1 receptor has been described mainly in the central
nervous system and endocrine tumours, so the scarcity of its
expression in colorectal tissue is not surprising.
Previously, two studies have described somatostatin receptor
expression in colorectal cancer specimens, the first using autoradi-
ography and the second, membrane ligand binding. In the autora-
diographic studies, the ligands used were '251[Tyr3] octreotide,
which has high affinity for hSSTR2 and 5, modest affinity for
hSSTR3 and virtually no affinity for hSSTR1 or 4, and['251]SS28,
which binds to all receptor subtypes with high affinity but has
highest affinity for hSSTR5 (Reubi et al, 1994). The results of
these studies demonstrated expression of receptors in 3/14
colorectal cancers and in all peritumoral veins. This method does
not adequately distinguish between hSSTR2, 3 and 5. We have not
specifically sought to look for peritumoral veins. The membrane-
binding studies reported by Miller et al (1992) using['251]SS14,
found binding in 17/23 of colorectal cancers, although this was of
low affinity; SS14 will bind to all receptor subtypes with high
affinity. The frequency of expression in this study is of the same
order as in our study. It may be that the low-affinity binding was
previously caused by ligand catabolism as SS14 is rapidly
degraded (Patel et al, 1981), or is indicative ofuncoupled receptor.
Somatostatin receptor expression has previously been demon-
strated by RT-PCR in human colon cancer cell lines (hSSTR1 and
2) (Eden and Taylor, 1993; Warhurst et al, 1995) and normal
colonic mucosa (hSSTR1 and 2) (Warhurst et al, 1995), but not in
matched tumour/mucosal pairs. hSSTR5 expression in colon
cancer cell lines or tissue has not been analysed previously.
These studies are important as they show which of the somato-
statin receptors it may be possible to target in patients with colon
cancer. We have identified the two receptor subtypes most
commonly expressed in colon cancer: hSSTR2 and hSSTR5.
hSSTR5 is only occasionally expressed by metastases, and expres-
sion in primary tumours, when present, is patchy. The hSSTR5
subtype is, therefore, unlikely to be an appropriate target for
therapy. In contrast, the expression of the hSSTR2 gene is almost
ubiquitous in colon cancer and this includes metastasis. In situ
studies also show that its expression is homogeneous. However,
these and other studies show that most cell types express the
hSSTR2 (Bell and Reisine, 1993; Yamada et al, 1993), hence
selectivity of action is not possible.
In transfection studies, the somatostatin receptors have been
shown to be coupled to a variety of signalling pathways via
heterotrimeric G-protein complexes. All appear to be linked to the
inhibition of adenyl cyclase (Patel et al, 1994), but this pathway
does not appear to be ofprimary importance in the antiproliferative
activity ofsomatostatin. Both hSSTR2 and hSSTR1 exhibit growth-
inhibitory effects via tyrosine phosphatases in vitro (Leibow et al,
1989; Todisco et al, 1994; Buscail et al, 1994) and, hence, can
directly antagonize the effects of growth factors, such as EGF
(Vidal et al, 1994). hSSTR5 is also linked to the inhibition ofprolif-
eration in vitro,although the mechanism appears to be the inhibition
of intracellular calcium mobilization (Buscail et al, 1995).
hSSTR2 is the receptor subtype to which the currently marketed
analogue, octreotide, binds with highest affinity (Lamberts et al,
1996). Vapreotide (RC160) and lanreotide (BIM23014) bind to
hSSTR5 with higher affinity than octreotide. Lanreotide, but not
vapreotide, also binds to hSSTR2 with higher affinity than
octreotide, and all three analogues have a lower affinity for the
other three subtypes (O'Carroll et al, 1994; Lamberts et al, 1996).
Some reports have suggested that vapreotide (RC160) is associ-
ated with tyrosine phosphatase activity but octreotide is not
(Todisco et al, 1994), although on the basis of the subtype speci-
ficity of the analogues, it is difficult to explain this. hSSTR5 has
not, to date, been linked to phosphatase activity. All of these
analogues have demonstrated antiproliferative activity in cell
culture and xenograft studies (Singh et al, 1986; Qin et al, 1992;
Radulovic et al, 1993; Stewart et al, 1994; van Eijck et al, 1994).
Some studies have been carried out using octreotide in patients
with advanced gastrointestinal cancer, although the results have
been contradictory: three trials failed to demonstrate clinical
response to treatment (Klijn et al, 1990; Krook et al, 1993; Palmer
Smith et al, 1994). The first of these trials (Klijn et al, 1990), a
phase II study of 34 patients with metastatic pancreatic and
gastrointestinal malignancies treated with octreotide, showed no
objective responses to treatment and most patients did not demon-
strate disease stabilization. In the second study (Krook et al, 1993),
260 patients with advanced colorectal cancer were randomized to
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receive either octreotide, 150 jig three times daily, or best
supportive care. No difference in survival was demonstrated. In
the final small study (Palmer Smith et al, 1994), 12 patients with
colorectal cancer were treated with octreotide, but no responses
seen. These findings contrast with the most recently published
study (Cascinu et al, 1995) in which patients with advanced
colorectal (24 vs 22), pancreatic (16 vs 16) and gastric (15 vs 14)
malignancies were randomized to octreotide or best supportive
care. Although no patient achieved an objective response, median
survival in the octreotide-treated group was significantly improved
at 20 vs 11 weeks. The octreotide-treated group was also more
likely to exhibit disease stabilization (45% vs 15%). The small
numbers of patients, lack of a placebo group and the disparate
conditions treated make it difficult to accept the results of this
study fully. In general, the need for well-constructed studies of
sufficient size is clear.
In summary, this work demonstrates that there is almost ubiqui-
tous expression of hSSTR2 mRNA in colonic tumours. This
finding lends some support to the use of potent long-acting
somatostatin analogues with direct growth-inhibitory effects via
the hSSTR2 receptor in patients with colon cancer. However, the
widespread expression of this receptor in most cell types indicates
that there is unlikely to be sufficient specificity to allow a useful,
direct, anti-tumour effect, although this does not preclude somato-
statin analogues from having indirect antiproliferative activity. In
addition, it would be necessary first to develop methods, which
confirm both the presence of receptor protein and of appropriate
growth-inhibitory signalling pathways in cancer tissue, as well as
transfected cell lines. hSSTR5 is not an appropriate target for the
direct effects of somatostatin analogues in colon cancer, as its
expression is frequently lost with tumour progression, but it
warrants investigation as a tumour suppressor.
ABBREVIATIONS
hSSTR, human somatostatin receptor; SS14, SS28, somatostatin
14 and 28 respectively; PCR, polymerase chain reaction; RT,
reverse transcription; ISH, RNA in situ hybridization; RT-PCR,
reverse transcription-polymerase chain reaction; DMSO, dimethyl
sulphoxide; MMLV-RT, mouse Moloney leukaemia virus reverse
transcriptase; DTT, dithiothreitol; dNTP, deoxynucleotide; SSC,
standard saline citrate; BSA, bovine serum albumin.
ACKNOWLEDGEMENT
SAML was financed by the generous support of the people of
Guernsey through the Wessex Medical Trust Guernsey Research
Fellowship.
NOTE ADDED IN PROOF
Our preferred primer sequences for hSSTR3 are now: forward
GGCCCTCCCGCCGTGT and reverse CGCTCCTGCCCGCTGGT.
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